Safety processes and regulations apply to custom-made medicines, which differ from traditional pharmacies. Now, however, ...

A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...

Novo Nordisk, the maker of the semaglutide products Ozempic and Wegovy, has filed lawsuits against 40 pharmacies, spas and ...

By Arasu Kannagi Basil and Prakhar Srivastava (Reuters) -Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer ...

Robert F. Kennedy Jr. criticized Ozempic and Danish pharmaceutical company Novo Nordisk, arguing that fixing the food supply ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

With 890 million people affected globally and 42% of American adults classified as obese, the allure of a "miracle" weight ...

Semaglutide – a key ingredient in Ozempic and Wegovy – was associated with a lower risk of opioid overdose in patients with Type 2 diabetes and opioid use disorder, research shows.

BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

The arrival of GLP-1 analog drugs (such as Wegovy) marked a huge shift in the weight-loss drug market. These drugs have been ...

An emerging market for compounded weight loss injections that mimic brand-name drugs such as Ozempic, Wegovy, Mounjaro and ...